链接：https://www.abinscience.cn/product/71/2205.html
名称：Anti-HBsAg Reference Antibody (Tobevibart, RUO)
货号：VK539056
种属反应性：Hepatitis B virus genotype A (HBV-A)
应用：ELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主：Human
同种型：IgG1-lambda
表达系统：Mammalian cells
克隆类型：Monoclonal
靶标：S/L-HBsAg/L glycoprotein
内毒素水平：Please contact the lab for this information.
纯度：>95% purity as determined by SDS-PAGE.
纯化方式：Protein A/G purified from cell culture supernatant.
Accession号：P03142
状态：Liquid
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
产品介绍：Anti-HBsAg Reference Antibody (Tobevibart, RUO)｜VK539056 是艾必赛生物（abinScience）推出的人源化单克隆参照抗体（人 IgG1-lambda），靶向乙型肝炎病毒（HBV）大包膜蛋白/乙肝表面抗原 S/L-HBsAg/L glycoprotein，种属反应性为 HBV genotype A，可作为乙肝血清学检测、PK/PD 研究、ADA 及功能性 assay（ELISA / FACS / functional assay / 体内研究）的阳性/药物参照质控工具。该抗体在哺乳动物细胞中表达，糖基化更接近天然构象，经 Protein A/G 纯化，纯度 >95%（SDS-PAGE），以液体形式保存在 0.01M PBS, pH 7.4 中；短期 2–8°C 用于频繁取用，长期建议 -20°C 至 -80°C（自收货日起 ≤12 个月）避反复冻融使用。（RUO，仅限科研/非临床用途）
HBV 大包膜蛋白（HBsAg）约 42 kDa，以"外部 Le-HBsAg"与"内部 Li-HBsAg"两种拓扑构象存在：外部构象负责将病毒附着于宿主细胞受体，决定种属特异性和肝嗜性，并诱导病毒粒子主要通过 caveolin 介导的内吞作用进入细胞；同时介导病毒膜与内体膜的融合，因此是乙肝病毒感染、预防性疫苗及抗病毒/免疫疗法研发的核心靶点。
Tobevibart（2645440-65-7）作为靶向 HBsAg 的研究级参照抗体，凭借哺乳动物表达体系带来的天然糖基化模式，适用于乙肝相关受体结合阻断、病毒进入抑制、血清 HBsAg 清除等机制研究，以及抗体药物临床前 PK、免疫原性（ADA）与功能性实验的方法学搭建。
产品购买联系方式：027-87433958/17302791434
邮箱：info@abinscience.com
参考文献：
Anti-PD-L1-IFN-α-adjuvanted HBsAg vaccine overcomes HBV immune tolerance through targeting both DCs and macrophages. PMID: 41355797
Efficient conjugation of anti-HBsAg antibody to modified core-shell magnetic nanoparticles (Fe(3)O(4)@SiO(2)/NH(2)). PMID: 34631485
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. PMID: 36316098
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. PMID: 35203653
A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection. PMID: 35862767
Effective production of anti-tetanus toxoid and anti-HBsAg human monoclonal antibodies by serum-free culture of hybridomas. PMID: 22359046
T-Cell Receptor β Chain and B-Cell Receptor Repertoires in Chronic Hepatitis B Patients with Coexisting HBsAg and Anti-HBs. PMID: 35889974
HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study. PMID: 39262443
Anti-HBsAg antibody mAb19-LS enhances antiviral immunity in humans with chronic hepatitis B. PMID: 42465932
Performance Evaluation of a HBsAg-Specific Immunoadsorbent Based on a Humanized Anti-HBsAg Monoclonal Antibody. PMID: 41007737
Antioxidative Flavonol Glucuronides and Anti-HBsAg Flavonol from Rotala rotundifolia. PMID: 24716106
The fixation of anti-HBsAg on plastic surfaces. PMID: 6799581
Association of leukocyte telomere length with anti-HBsAg antibody titer in Hepatitis-B recovered patients from the Pakistani population. PMID: 41146016
[Purification of recombinant humanized anti-HBsAg Fab antibody by affinity chromatography]. PMID: 15367351
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal. PMID: 28806922
The anti-HBsAg (human type B hepatitis, surface antigen) and anti-HBeAg (human type B hepatitis, e antigen) C18 dibenzocyclooctadiene lignans from Kadsura matsudai and Schizandra arisanensis. PMID: 14600364
Hepatitis B vaccine: current issues. PMID: 9296247
Synthesis and biological evaluation of esculetin derivatives as potential anti-HBV agents. PMID: 37056462
CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update. PMID: 33783302
Production of recombinant humanized anti-HBsAg Fab fragment from Pichia pastoris by fermentation. PMID: 15943904
[PREVALENCE OF HBsAg AND anti-HBs CARRIERS IN PREGNANT WOMEN WHO RESIDE IN DIFFERENT ENDEMIC AREAS LOCATED IN CENTRAL-SOUTHERN DEPARTAMENTS OF PERU]. PMID: 12196812
Liposome-mediated DNA vaccination. PMID: 9037176
An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors. PMID: 29675010
Cytosolic delivery of HBsAg and enhanced cellular immunity by pH-responsive liposome. PMID: 32474120
Bacteriophage-mediated nucleic acid immunisation. PMID: 14734182
Decreased expression of HBV surface antigen (HBsAg) with sK122R and sV96A co-mutation is associated with an ineffective antibody response in a chronic hepatitis B patient. PMID: 37015318
Seroprevalence of hepatitis B virus infection and seroconvertion to anti-HBsAg in laboratory staff in Goiania, Goias. PMID: 15821790
Protection level of anti-hepatitis B vaccine and immunoglobulin in a pediatric Cameroonian population. PMID: 38204806
Antihepatitis activity (anti-HBsAg and anti-HBeAg) of C19 homolignans and six novel C18 dibenzocyclooctadiene lignans from Kadsura japonica. PMID: 16041651
Correlation Between Vitamin D Status and HBsAg Antibody Levels in Indonesian Adolescents Immunised Against Hepatitis B. PMID: 38021059
Characterisation of plasmablast-derived HBsAg-specific antibody and its structural basis for binding to native HBsAg dimer. PMID: 41663152
Anti-HBsAg assay using the Ausria system with standard antigen dilutions. PMID: 1204948
Potential role of liver-resident CD3+ macrophages in HBV clearance in a mouse hepatitis B model. PMID: 40143948
Engineering a dual-antigen mRNA vaccine to restore immune control in chronic hepatitis B. PMID: 42315521
Production of anti-HBsAg monoclonal antibodies. PMID: 2465803
Syntheses of C(18) dibenzocyclooctadiene lignan derivatives as anti-HBsAg and anti-HBeAg agents. PMID: 15698772
[Anti-HBsAg herbs employing ELISA technique]. PMID: 2268945
Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy. PMID: 18410348
详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司
官方网址：【中文】https://www.abinscience.cn
【英文】https://www.abinscience.com
武汉艾必赛生物技术有限公司成立于 2023 年，是 abinScience 在亚洲地区设立的官方全资子公司，全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。
依托严格的产品研发体系和国际化的质量管理标准，武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作，现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系，面向区域内科研机构、高校实验室与生物医药企业，提供稳定、高效、可信赖的产品与服务。
核心业务覆盖：
? 抗体产品（单抗、多抗、重组抗体等）
? 蛋白与多肽试剂（标签蛋白、功能蛋白等）
? 分子与细胞实验相关耗材
? 定制化研发服务（蛋白表达、抗体定制、亲和力成熟等）
? 科研供应链整合与项目配套支持
武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念，为亚太地区的生命科学研究持续注入高质量动能。
返回顶部
扫一扫关注我们